Fatty acid synthesis restricts HIV-1 infection through regulation of the nuclear envelope in CD4+ T cells

Viruses are masterful hijackers. To turn a healthy human cell into a factory for new viruses, a pathogen must not only enter the cell but also navigate its internal defenses and reach the command center where the cell's genetic instructions are kept. For the human immunodeficiency virus, known as HIV-1, this journey is particularly treacherous. The virus must cross a double-layered membrane called the nuclear envelope to insert its own genetic code into the host's DNA. If it fails to breach this barrier, the infection stalls. Scientists have long known that certain proteins in the cell can block this process, acting as molecular guards. However, the role of the cell's metabolism—its chemical engine that fuels growth and repair—has remained a mystery. Does the cell's internal fuel supply help the virus, or does it build stronger walls against it? Understanding this balance is critical because the cells that successfully harbor the virus form a hidden reservoir that makes curing HIV nearly impossible.

A team of researchers at the Ragon Institute, MIT, and Harvard set out to map the metabolic pathways that control whether a cell resists or surrenders to HIV-1. They focused on a specific type of immune cell, the CD4+ T cell, which is the primary target of the virus. Instead of looking for known viral blockers, they asked a broader question: what happens if we tweak the cell's chemistry? They treated thousands of these cells with a library of 240 different small molecules, each designed to slow down or stop a specific metabolic process. They then exposed the cells to a single round of HIV-1 and watched to see which chemical changes made the cells more vulnerable. The results were surprising. Rather than finding that starving the cell of energy helped the virus, they discovered that most of the metabolic inhibitors actually made the cells more susceptible. The virus found it easier to infect cells that were chemically stressed. However, a specific group of inhibitors told a different story. When the researchers blocked the cell's ability to make its own fats, the cells became highly susceptible to infection.

The researchers identified that the key to this resistance lies in the cell's ability to synthesize fatty acids from scratch. This process, known as de novo fatty acid synthesis, is like a factory line that builds the raw materials needed to construct the cell's membranes. When the team used drugs to shut down the enzymes that drive this factory—specifically one called fatty acid synthase, or FASN—the cells lost their ability to resist the virus. The infection rate jumped significantly. To prove that this was not just a side effect of the drugs making the cells sick, the researchers added back the missing fats from the outside. When they supplied the cells with pre-made fatty acids, the cells regained their resistance, and the infection rate dropped back to normal levels. This confirmed that the virus was not winning because the cells were dying, but because they were missing a specific structural component they usually build for themselves.

The study then moved to the microscopic level to see what was physically different about the cells that had lost their ability to make fat. Using high-powered electron microscopes, the team examined the architecture of the nuclear envelope. In healthy cells, this barrier is a smooth, tight double wall. In the cells where fat synthesis was blocked, the wall became distorted and irregular. The space between the inner and outer layers of the nuclear envelope widened and became uneven, creating gaps in the structure. The researchers found that the cells were trying to compensate for the lack of their own fat by incorporating longer, more flexible fat chains from their environment, but this change altered the physical properties of the membrane. It was as if the cell's protective shell had become too loose and pliable, allowing the virus to slip through more easily. The virus, which normally has to navigate a tight, structured gate, found a compromised barrier that was easier to breach.

This discovery also revealed a new way to think about how the virus interacts with the cell's environment. The susceptibility of a cell to HIV-1 is not just a fixed trait of the cell itself; it depends on the chemical ingredients available in its surroundings. If the cell can make its own fats, it builds a strong barrier. If it cannot, it must rely on the fats floating nearby. If those external fats are not the right kind—specifically, if they are not saturated fats like palmitate—the barrier fails. The researchers tested this by feeding the cells different types of fats. Only saturated fats, which are straight and rigid, could restore the barrier and stop the infection. Unsaturated fats, which are bent and flexible, could not. This suggests that the local environment of a cell, such as the lipid composition of the blood or tissue fluid, could influence how easily the virus establishes an infection.

Finally, the team explored whether this metabolic weakness could be turned into a therapeutic advantage. They tested how the cells responded to existing antiviral drugs that target the virus's entry into the nucleus. One such drug, PF74, works by jamming the mechanism the virus uses to pass through the nuclear pores. In normal cells, this drug is effective, but in the cells where fat synthesis was blocked, the drug became ten times more potent. The compromised nuclear envelope made the virus even more dependent on the specific entry route that the drug blocks. This finding suggests that the metabolic state of a cell can be harnessed to make current treatments work better. While the researchers did not test this in humans, they noted that drugs that inhibit fat synthesis are already being studied for other conditions, such as liver disease. If these drugs can be safely combined with HIV treatments, they might help clear the virus more effectively by making the cells' defenses more permeable to the medication.

The study concludes that the battle against HIV-1 is fought not just with immune proteins, but with the very building blocks of the cell. The ability to synthesize fats is a crucial defense mechanism that maintains the structural integrity of the nuclear envelope. When this ability is lost, the physical barrier weakens, and the virus gains access. This work shifts the perspective on viral resistance, showing that it emerges from the complex interplay between a cell's internal machinery and the chemical environment it inhabits. By understanding these metabolic dependencies, scientists may uncover new ways to strengthen the cell's natural defenses or to weaken the virus's ability to hide. The findings offer a fresh look at the earliest moments of infection, revealing that the cell's metabolic state is a decisive factor in whether a virus succeeds or fails.